发明名称 Antipsychotic treatment based on SNP genotype
摘要 The present invention relates to the prediction of antipsychotic treatment efficacy based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
申请公布号 US9328387(B2) 申请公布日期 2016.05.03
申请号 US200812675598 申请日期 2008.09.10
申请人 Vanda Pharmaceuticals, Inc. 发明人 Lavedan Christian;Volpi Simona;Licamele Louis;Polymeropoulos Mihael H.
分类号 C12Q1/68;C12P19/34 主分类号 C12Q1/68
代理机构 Hoffman Warnick LLC 代理人 Hoffman Warnick LLC
主权项 1. A method of treating a human individual with at least one psychotic symptom comprising: a) determining the individual's genotype at the single nucleotide polymorphism (SNP) locus rs4528226; and b) administering to the individual a first effective amount of between about 2 mg/day and about 24 mg/day of iloperidone, a pharmaceutically-acceptable salt thereof, a metabolite thereof, or a pharmaceutically-acceptable salt of a metabolite thereof in the case that the individual's genotype at rs4528226 is GT; or administering to the individual a second effective amount of iloperidone, a pharmaceutically-acceptable salt thereof, a metabolite thereof, or a pharmaceutically-acceptable salt of a metabolite thereof in the case that the individual's genotype at rs4528226 is not GT, wherein the second effective amount is between about 24 mg/day and about 50 mg/day and greater than the amount administered to an individual that has a GT genotype at the rs4528226 locus.
地址 Washington DC US